Skip to main content
SLP
NASDAQ Technology

Simulations Plus Reports Strong Q2 Net Income & Operational Efficiency, Boosts R&D Investment

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Health Tech Stocks · Healthcare
Sentiment info
Positive
Importance info
7
Price
$13.04
Mkt Cap
$262.711M
52W Low
$11.09
52W High
$36.45
52W Position info
18% above low
Off High info
64% below high
Rel. Volume info
4.0× avg
Market data snapshot near publication time

SLP sits 18% above its 52-week low of $11.09 on elevated volume (4.0× avg).

Summary

Simulations Plus reported a 48% increase in Q2 net income and a 108% rise in operating income, driven by improved margins and cost efficiencies, alongside increased strategic R&D investment.


Key Events · Earnings and Guidance · SLP

  • Strong Q2 Net Income Growth

    Net income for the three months ended February 28, 2026, increased by 48% to $4.5 million ($0.22 EPS) from $3.1 million ($0.15 EPS) in the prior year period.

  • Significant Operating Income Improvement

    Income from operations for Q2 FY26 rose by 108% to $5.6 million, compared to $2.7 million in Q2 FY25, reflecting enhanced operational efficiency.

  • Improved Gross Margins

    Overall gross margin expanded to 66% in Q2 FY26 from 59% in Q2 FY25, primarily due to lower software amortization expenses and increased service-related revenues.

  • Increased Strategic R&D Investment

    Research and development expenses increased by 62% to $3.5 million in Q2 FY26, demonstrating continued investment in innovation, including AI-driven modeling and cloud-enabled platforms.


Analysis · SLP · Technology

Simulations Plus, Inc. delivered a robust second quarter, with net income surging 48% and operating income more than doubling, driven by improved gross margins and significant cost reductions in sales, marketing, and general & administrative expenses. The company also substantially increased its R&D investment, focusing on an integrated, cloud-enabled modeling ecosystem with AI capabilities, signaling a strategic commitment to future growth. While the top-line revenue growth was modest, the operational efficiency gains and strong cash flow from operations highlight effective management in a competitive biopharma sector. This detailed quarterly report follows a preliminary announcement, providing comprehensive insights into the company's financial health and strategic direction.

At the time of this filing, SLP was trading at $13.04 on NASDAQ in the Technology sector, with a market capitalization of approximately $262.7M. The 52-week trading range was $11.09 to $36.45. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

SLP - Latest Insights

SLP
Jul 09, 2026, 4:10 PM EDT
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $18.47
Real-time Price: $18.33 info
Change: -$0.1398 (-0.76%) info
Market Cap: $370.721M info
SLP
Jul 09, 2026, 4:05 PM EDT
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $18.36
Real-time Price: $18.33 info
Change: -$0.0297 (-0.16%) info
Market Cap: $370.721M info
SLP
Jul 09, 2026, 4:01 PM EDT
Filing Type: PREM14A
Importance Score:
9
Price at Filing: $18.34
Real-time Price: $18.33 info
Change: -$0.010 (-0.05%) info
Market Cap: $370.721M info
SLP
Jun 17, 2026, 4:01 PM EDT
Filing Type: 8-K
Importance Score:
10
Price at Filing: $18.25
Real-time Price: $18.33 info
Change: +$0.080 (+0.44%) info
Market Cap: $370.721M info
SLP
Jun 16, 2026, 9:00 AM EDT
Filing Type: 8-K
Importance Score:
10
Price at Filing: $16.40
Real-time Price: $18.33 info
Change: +$1.93 (+12%) info
Market Cap: $370.721M info